Most recent FDA COVID-19 updates

By Jenni Spinner contact

- Last updated on GMT

(wildpixel/iStock via Getty Images Plus)
(wildpixel/iStock via Getty Images Plus)

Related tags: Fda, COVID-19, Coronavirus, Testing

The US agency continues to put out informational resources, issue EUAs for tests and treatments, and monitor industry activity related to the virus.

The US Food and Drug Administration (FDA) has maintained its status as a resource of advice and action for pharmaceutical, clinical trial and life sciences professionals as the virus rages on around the globe. Read on to learn more about the agency's latests moves related to the COVID-19 pandemic.

Test authorizations

The agency has issued a number of emergency use authorizations (EUAs) around testing for the virus. One is an EUA reissued for LabCorp’s COVID-19 RT-PCR test, including two new indications for use:

  • Testing patients without any symptoms
  • Permitting pooled sample testing.

The FDA also issued EUAs for Two molecular diagnostic tests for qualitative detection of SARS-CoV-2. One was issued to Eli Lilly for its SARS-CoV-2 assay; the other was to Sandia national Laboratories, for the SNL-NM 2019 nCoV RT-PCR diagnostic assay.

Offsite test guidance

The FDA posted a new template​ designed to help companies develop and submit EUA requests for offsite diagnostic tests. The EUAs would cover tests allowed to be performed at home, offices, schools and other non-medical settings, without a prescription.

Details covered in the template include recommendations for validation when a sample is to be collected and analyzed, and results are to be returned without the need to send a sample to a lab for analysis. The resource also outlines the recommended performance for this type of test, including sensitivity and specificity.

Responses to date

The agency issued another update to its updated FDA COVID-19 Response At-A-Glance Summary​ document. The resource includes facts, figures and key components of FDA response efforts.

Counterfeit products

The FDA and Federal Trade Commission (FTC) continue to scour the market for products falsely claiming to prevent, treat or cure the virus; to date, no such products have been okayed by the FDA. The latest companies to receive a warning letter: 21st Century LaserMed Pain and Regenerative Medicine Institute.

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Related suppliers

Follow us

Products

View more

Webinars